Advertisement
Mayo Clinic Proceedings Home
Advanced SearchSave search
Original Article|Articles in Press

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab or Sotrovimab for Mild to Moderate Coronavirus Disease-2019

Open AccessPublished:June 22, 2022DOI:https://doi.org/10.1016/j.mayocp.2022.06.015
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab or Sotrovimab for Mild to Moderate Coronavirus Disease-2019
Previous ArticlePituitary Adenoma Incidence, Management Trends, and Long-term Outcomes: A 30-Year Population-Based Analysis
Next ArticleAssociation of Lifestyle Behaviors With Hearing Loss
      This paper is only available as a PDF. To read, Please Download here.

      ABSTRACT

      Objective

      To describe and compare the clinical outcomes of bamlanivimab-etesevimab, casirivimab-imdevimab and sotrovimab treatment of mild to moderate coronavirus disease-2019 during the SARS-CoV-2 B.1.617.2 Delta surge.

      Methods

      Retrospective study of high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab and sotrovimab for mild to moderate COVID-19 during August 1 – December 1, 2021. Rates of severe disease, hospitalization, intensive care unit admission and death were assessed.

      Results

      Among 10,775 high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab or sotrovimab for mild to moderate COVID-19 during the Delta surge, 287 patients (2.7%) developed severe disease that led to hospitalization, oxygen supplementation or death within 30 days after treatment. The rates of severe disease were low among patients treated with bamlanivimab-etesevimab (1.2%), casirivimab-imdevimab (2.9%), and sotrovimab (1.6%; p<0.01). The higher rate of severe outcomes among patients treated with casirivimab-imdevimab may be related to a significantly lower COVID-19 vaccination rate in that cohort. Intensive care unit admission was comparable among patients treated with the anti-spike monoclonal antibody products (1.0%, 1.0%, 0.4%, respectively).

      Conclusion

      This real-world study of a large cohort of high-risk patients demonstrates low rates of severe disease, hospitalization, ICU admission, and mortality after treatment with bamlanivimab-etesevimab, casirivimab-imdevimab and sotrovimab for mild to moderate COVID-19 during the SARS-CoV-2 Delta surge.

      ABBREVIATIONS:

      BMI (body mass index), CI (confidence interval), COVID-19 (coronavirus disease-2019), EHR (electronic health record), EUA (emergency use authorization), FDA (Food and Drug Administration), ICU (intensive care unit), IQR (interquartile range), MASS (monoclonal antibody screening score), MATRx (Monoclonal Antibody Treatment Program), PCR (polymerase chain reaction), SARS-COV-2 (Severe Acute Respiratory Syndrome-coronavirus-2)

      Article Info

      Publication History

      Accepted: June 2, 2022
      Received in revised form: May 19, 2022
      Received: February 22, 2022

      Publication stage

      In Press Accepted Manuscript

      Footnotes

      CRediT Author statement:

      Raymund R Razonable: Conceptualization, Resources, Funding acquisition, Methodology, Writing – Original Draft, Supervision, Project administration.

      John O’Horo: Methodology, Data curation, Formal Analysis, Writing – Review & Editing, Supervision;

      Douglas Challener: Methodology, Data curation, Writing – Review & Editing;

      Lori Arndt: Writing – Review & Editing;

      Richard Arndt: Writing – Review & Editing;

      Caroline G. Clune: Writing – Review & Editing;

      Tracy L. Culbertson: Writing – Review & Editing

      Scott T. Hall: Writing – Review & Editing

      Alexander Heyliger: Writing – Review & Editing

      Tammy A. Jackson: Writing – Review & Editing

      Brian D. Kennedy: Writing – Review & Editing

      Jennifer Larsen: Writing – Review & Editing

      Sarah N. Hanson: Writing – Review & Editing

      Perry Sweeten: Writing – Review & Editing

      Sidna M. Tulledge-Scheitel: Writing – Review & Editing, Project administration, Supervision;

      Ravindra Ganesh: Conceptualization, Writing – Review & Editing, Project administration, Supervision

      Identification

      DOI: https://doi.org/10.1016/j.mayocp.2022.06.015

      Copyright

      © 2022 Mayo Foundation for Medical Education and Research

      User License

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX